限盐饮食有益于常染色体显性多囊肾病的管理
该研究对HALT-PKD临床试验进行事后分析,评估限盐对常染色体显性多囊肾病(ADPKD)患者总肾脏体积增长或估算肾小球滤过率(eGFR)变化的影响。结果显示,在eGFR>60 ml/min/1.73 m2的患者中,尿钠排泄与肾脏增长显著相关;在eGFR 25-60 ml/min/1.73 m2的患者中,平均尿钠排泄与复合终点风险增加及eGFR下降更快显著相关。因此,限盐有益于ADPKD的管理。
要点
- 在eGFR>60 ml/min/1.73 m2的ADPKD患者中,尿钠排泄与肾脏增长显著相关。
- 在eGFR 25-60 ml/min/1.73 m2的患者中,平均尿钠排泄与复合终点风险增加及eGFR下降更快显著相关。
- 限盐饮食有益于ADPKD的管理。
核心结论
- 限盐有益于常染色体显性多囊肾病(ADPKD)的管理。
研究设计与样本
- 对HALT-PKD临床试验(肾素-血管紧张素阻断治疗ADPKD)进行事后分析,所有患者均开始接受低于100 mEq的钠饮食。
- 采用线性混合模型,在eGFR>60 ml/min/1.73 m2的患者(研究A)中评估饮食钠对总肾脏体积或eGFR变化率的影响,在eGFR 25-60 ml/min/1.73 m2的患者(研究B)中评估对复合终点(eGFR降低50%、终末期肾病或死亡)风险或eGFR下降率的影响。
主要发现
- 试验期间,研究A和研究B的尿钠排泄分别平均每月显著下降0.25和0.41 mEq/24小时。
- 在研究A中,平均和时间变化的尿钠排泄均与肾脏增长显著相关(每18 mEq尿钠排泄分别为0.43%/年和0.09%/年)。
- 在研究A中,平均尿钠排泄与更快的eGFR下降无显著相关(每18 mEq尿钠排泄为-0.07 ml/min/1.73m2/年)。
- 在研究B中,平均(而非时间变化)尿钠排泄与复合终点风险增加显著相关(每18 mEq尿钠排泄的风险比为1.08),并与更快的eGFR下降显著相关(每18 mEq尿钠排泄为-0.09 ml/min/1.73m2/年)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CRISP study of polycystic kidney disease (PKD) found that urinary sodium excretion associated with the rate of total kidney volume increase. Whether sodium restriction slows the progression of Autosomal Dominant PKD (ADPKD) is not known. To evaluate this we conducted a post hoc analysis of the HALT-PKD clinical trials of renin-angiotensin blockade in patients with ADPKD. Linear mixed models examined whether dietary sodium affected rates of total kidney volume or change in estimated glomerular filtration rate (eGFR) in patients with an eGFR over 60 ml/min/1.73 m2 (Study A) or the risk for a composite endpoint of 50% reduction in eGFR, end-stage renal disease or death, or the rate of eGFR decline in patients with an eGFR 25-60 ml/min/1.73 m2 (Study B) all in patients initiated on an under100 mEq sodium diet. During the trial urinary sodium excretion significantly declined by an average of 0.25 and 0.41 mEq/24 hour per month in studies A and B, respectively. In Study A, averaged and time varying urinary sodium excretions were significantly associated with kidney growth (0.43%/year and 0.09%/year, respectively, for each 18 mEq urinary sodium excretion). Averaged urinary sodium excretion was not significantly associated with faster eGFR decline (-0.07 ml/min/1.73m2/year for each 18 mEq urinary sodium excretion). In Study B, the averaged but not time-varying urinary sodium excretion significantly associated with increased risk for the composite endpoint (hazard ratio 1.08 for each 18 mEq urinary sodium excretion) and a significantly faster eGFR decline (-0.09 ml/min/1.73m2/year for each mEq 18 mEq urinary sodium excretion). Thus, sodium restriction is beneficial in the management of ADPKD.
引用
- Torres VE, Abebe KZ, Schrier RW, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2016. PMID: 27993381. doi:10.1016/j.kint.2016.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。